SCHEMBL30730633

SCHEMBL30730633

Cc1noc(CC(=O)N2CCC(O)(c3nc(-c4ccc(F)cc4)no3)CC2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.45
MAPK1 P28482 2/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
HPGD P15428 1/20 0.43
MAPT P10636 4/20 0.41
HDAC4 P56524 2/20 0.41
HDAC6 Q9UBN7 2/20 0.41
HTT P42858 2/20 0.41
TACR3 P29371 1/20 0.39
POLB P06746 2/20 0.39
ALDH1A1 P00352 3/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
DGAT1 O75907 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
GSTP1 P09211 1/20 0.37
GRM5 P41594 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30730632 0.85 LMNA (0.45) LMNAMAPK1ALOX15TSHRHPGD
SCHEMBL30730514 0.81 LMNA (0.51) LMNAMAPK1ALOX15TSHRHPGD
SCHEMBL30730576 0.81 LMNA (0.53) LMNAMAPK1ALOX15TSHRHPGD
SCHEMBL30730558 0.80 LMNA (0.71) LMNAMAPK1ALOX15TSHRMAPT
SCHEMBL30730575 0.76 LMNA (0.50) LMNAMAPK1ALOX15TSHRHPGD
SCHEMBL30730515 0.75 LMNA (0.45) LMNAMAPK1ALOX15TSHRHPGD
SCHEMBL30730692 0.75 DPP4 (0.34) GRM5
SCHEMBL32676597 0.74 HSD11B1 (0.35) ALDH1A1
SCHEMBL30730534 0.74 TSHR (0.48) LMNAMAPK1ALOX15TSHRMAPT
SCHEMBL32677165 0.73 LMNA (0.43) LMNAMAPK1ALOX15TSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US claimed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO claimed
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US disclosed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE FNTB, PDE7A, TBL3 LMNA 1838/4885MAPK1 1861/4885ALOX15 2647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.